159 related articles for article (PubMed ID: 26493309)
1. Endogenous TSH levels at the time of
Vrachimis A; Riemann B; Mäder U; Reiners C; Verburg FA
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):224-231. PubMed ID: 26493309
[TBL] [Abstract][Full Text] [Related]
2. TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer.
Ju N; Hou L; Song H; Qiu Z; Wang Y; Sun Z; Luo Q; Shen C
Eur Thyroid J; 2023 Aug; 12(4):. PubMed ID: 37022724
[TBL] [Abstract][Full Text] [Related]
3. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
[TBL] [Abstract][Full Text] [Related]
4. Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?
Hasbek Z; Turgut B
Mol Imaging Radionucl Ther; 2016 Jun; 25(2):79-84. PubMed ID: 27277324
[TBL] [Abstract][Full Text] [Related]
5. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
6. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
Piccardo A; Puntoni M; Ferrarazzo G; Foppiani L; Bottoni G; Altrinetti V; Treglia G; Naseri M; Dib B; Cabria M; Trimboli P; Massollo M; Giovanella L
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1218-1223. PubMed ID: 29460027
[TBL] [Abstract][Full Text] [Related]
7. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma.
Diessl S; Holzberger B; Mäder U; Grelle I; Smit JW; Buck AK; Reiners C; Verburg FA
Clin Endocrinol (Oxf); 2012 Apr; 76(4):586-92. PubMed ID: 22059804
[TBL] [Abstract][Full Text] [Related]
8. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival.
Piccardo A; Arecco F; Puntoni M; Foppiani L; Cabria M; Corvisieri S; Arlandini A; Altrinetti V; Bandelloni R; Orlandi F
Clin Nucl Med; 2013 Jan; 38(1):18-24. PubMed ID: 23242039
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
10. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
12. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
13. Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer.
Verburg FA; Mäder U; Luster M; Hänscheid H; Reiners C
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1390-8. PubMed ID: 26070546
[TBL] [Abstract][Full Text] [Related]
14. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.
Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Chami L; Travagli JP; Hartl D; Lumbroso J; Chougnet C; Lacroix L; Baudin E; Schlumberger M; Leboulleux S
Endocr Relat Cancer; 2011 Apr; 18(2):R29-40. PubMed ID: 21183629
[TBL] [Abstract][Full Text] [Related]
15. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
[TBL] [Abstract][Full Text] [Related]
16. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
[TBL] [Abstract][Full Text] [Related]
18. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
Ma C; Xie J; Kuang A
J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
[TBL] [Abstract][Full Text] [Related]
19. Relationship between Variation of Pre-ablation Stimulated Thyroglobulin and Distant Metastasis in Patients with Differentiated Thyroid Cancer.
Zhao T; Liang J; Li TJ; Li CX; Hui C; Yang K; Li F; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Jun; 37(3):315-9. PubMed ID: 26149144
[TBL] [Abstract][Full Text] [Related]
20. Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal.
Vallejo Casas JA; Mena Bares LM; Gálvez Moreno MA; Moreno Ortega E; Marlowe RJ; Maza Muret FR; Albalá González MD
Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):163-71. PubMed ID: 26563902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
